Kangmei Pharmaceutical (600518) To Realize Multiple Highlights Based on Core Advantages --- Buy

  • Contributor:TX Investment Consulting
  • Date:Mar 19, 2009
  • Pages:4pages
  • Price:$60.00
  • File Type: Adobe Acrobat Reader®
Download Free Adobe Acrobat Reader®

Research Reports Premium Services

-Get the full report for $60.00

-The financial products you have ordered will be sent to   you within 24 hours via e-mail.

Excerpts:

According to its 2008 annual report, the company realized total business turnover of Rmb1727mn (+33.74% yoy), operating profit of Rmb334mn (+38.39% yoy), net profit attributable to parent of Rmb295mn (+64.74% yoy), and diluted EPS of Rmb0.39. According to the company’s distribution plan, it sent five additional shares and five for transference & increase, plus pretax dividend cash of Rmb0.60.

 

We hereby up-regulate the company’s EPS to Rmb0.55 in 2009, and Rmb0.74 in 2010. Based on closing price of Rmb12.73 on March 18, 2009, its 2009 dynamic P/E ratio is 23x, and “Buy” rating is hereby given.


SSL